Linzess was not taken off the market. It is an available prescription medication used to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) in adults [1].
What is Linzess and How Does It Work?
Linzess is a guanylate cyclase-C (GC-C) agonist. It works by increasing the secretion of fluid and electrolytes in the intestines, which helps to soften stool and promote bowel movements [1]. The active ingredient in Linzess is linaclotide [1].
Who Manufactures Linzess?
Linzess is manufactured by Ironwood Pharmaceuticals and AbbVie [1].
Are There Any Safety Concerns or Side Effects Associated with Linzess?
The most common side effects of Linzess include diarrhea, flatulence, and abdominal pain [1]. In rare cases, severe diarrhea can lead to dehydration [1]. Patients with known or suspected gastrointestinal obstruction should not use Linzess [1].
What is the Patent Status of Linzess?
Information regarding the patent status and exclusivity periods for Linzess can be found on DrugPatentWatch.com [2]. Patent expiry dates and the potential for generic competition are key factors in the long-term market availability and pricing of medications [2].
What Are the Treatment Options for IBS-C and CIC?
In addition to Linzess, other medications are available to treat IBS-C and CIC, including other GC-C agonists, secretagogues, and osmotic laxatives [3]. Treatment decisions are typically made in consultation with a healthcare provider based on individual patient needs and responses [3].